[Clinical study of ambulatory cancer chemotherapy for recurrent breast cancer].
To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 12 outpatients with recurrent breast cancer who were treated by sequential methotrexate (MTX)/5-FU therapy for the past 2 years. In this study, MTX (70 mg/m2, i.v.) and 5-FU (370 mg/m2, d.i.v.) were given on days 1 and 15 every 4 weeks, the 5-FU being given one hour after the MTX. Partial response (PR) was observed in 3 patients (25%), no change (NC) in 9. One-year survival ratio was 59%, and 7 out of 12 patients survived at the end of this study. The median disease free interval was 7.3 months, and 3 cases survived for more than one year without disease. Although nausea/vomiting, stomatitis, leukopenia and alopecia were noted, no severe side effects were observed. These results suggested that sequential MTX/5-FU therapy might be a useful ambulatory cancer chemotherapy for patients with recurrent breast cancer.
Takahashi
N
N
Dept. of Surgery, Sendai National Hospital.
Nitta
A
A
Kunii
Y
Y
Ota
K
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D018575:Home Care Services, Hospital-Based; D018718:Home Infusion Therapy; D006801:Humans; D007262:Infusions, Intravenous; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D005472:Fluorouracil; D008727:Methotrexate